2. >>Focus On Asia
  3. >>China

Frontier Bets $52m On Potential Rival To Gilead's Veklury

 
• By Dexter Jie Yan

Frontier Biotechnologies is seeking to enroll roughly 1,200 hospitalized COVID patients in an international Phase II/III clinical trial to evaluate its bofutrelvir (FB2001) in competition with Gilead’s Veklury.

COVID antiviral intravenous infusion
Bofutrelvir (FB2001) is expected to fill the void of no small molecule-based antiviral treatment for hospitalized COVID-19 patients in China. • Source: Shutterstock

Shanghai-listed Frontier Biotechnologies Inc is betting CNY353m ($52m) to kickstart a pivotal global Phase II/III clinical trial to investigate an antiviral candidate in hospitalized patients with moderate to severe COVID-19.

More from China

More from Focus On Asia